文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症急性脑损伤患者的肺保护性机械通气:多中心随机临床试验(PROLABI)

Lung-Protective Mechanical Ventilation in Patients with Severe Acute Brain Injury: A Multicenter Randomized Clinical Trial (PROLABI).
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01
一句话结论在无ARDS的急性脑损伤患者中,与常规通气相比,肺保护性通气策略未降低28天死亡、机械通气依赖或ARDS发生率,且神经功能结局无获益。

这项多中心、开放标签、对照临床试验纳入190例急性脑损伤成人患者,随机接受肺保护性通气或常规通气策略,主要终点为28天死亡、呼吸机依赖和ARDS的复合终点。意向性分析显示,肺保护性通气组28天复合终点发生率为61.5%,常规通气组为45.3%(RR 1.35,95%CI 1.03-1.79,P=0.025);死亡率分别为28.9%和15.1%(RR 1.91,95%CI 1.06-3.42,P=0.02);呼吸机依赖率分别为42.3%和27.9%(RR 1.52,95%CI 1.01-2.28,P=0.039);ARDS发生率分别为30.8%和22.1%(RR 1.39,95%CI 0.85-2.27,P=0.179)。因资金终止,试验在纳入190例受试者后提前终止。作者结论认为,在无ARDS的急性脑损伤患者中,与常规策略相比,肺保护性通气策略未降低死亡率、脱机患者比例或ARDS发生率,且在神经功能结局方面无获益;由于提前终止,这些初步结果需在更大规模试验中证实。

要点

  • 在无ARDS的急性脑损伤成人中,肺保护性通气组28天复合终点(死亡、呼吸机依赖、ARDS)发生率为61.5%,常规通气组为45.3%(RR 1.35,95%CI 1.03-1.79,P=0.025)。
  • 肺保护性通气组28天死亡率为28.9%,常规通气组为15.1%(RR 1.91,95%CI 1.06-3.42,P=0.02)。
  • 肺保护性通气组28天呼吸机依赖率为42.3%,常规通气组为27.9%(RR 1.52,95%CI 1.01-2.28,P=0.039)。
  • 两组28天ARDS发生率分别为30.8%和22.1%(RR 1.39,95%CI 0.85-2.27,P=0.179),未达统计学显著。
  • 试验因资金终止在纳入190例后提前停止,作者认为这些初步结果需在更大规模试验中证实。

适用人群与场景

  • 成人急性脑损伤患者,且无ARDS,纳入本多中心随机临床试验。

研究设计与关键结果

  • 多中心、开放标签、对照临床试验,纳入190例成人急性脑损伤患者,随机分配至肺保护性通气策略组或常规通气策略组,主要终点为28天死亡、呼吸机依赖和ARDS的复合终点。
  • 意向性分析:肺保护性通气组28天复合终点发生率为61.5%,常规通气组为45.3%(RR 1.35,95%CI 1.03-1.79,P=0.025)。
  • 28天死亡率:肺保护性通气组28.9%,常规通气组15.1%(RR 1.91,95%CI 1.06-3.42,P=0.02)。
  • 28天呼吸机依赖率:肺保护性通气组42.3%,常规通气组27.9%(RR 1.52,95%CI 1.01-2.28,P=0.039)。
  • 28天ARDS发生率:肺保护性通气组30.8%,常规通气组22.1%(RR 1.39,95%CI 0.85-2.27,P=0.179)。
  • 神经功能结局:ICU出院时采用牛津残疾量表(Oxford Handicap Scale)评估,6个月时采用格拉斯哥结局量表(Glasgow Outcome Scale)评估;作者结论认为肺保护性通气在神经功能结局方面无获益。
  • 试验因资金终止在纳入190例受试者后提前终止。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、随机对照临床试验。
  • 局限:试验因资金终止在纳入190例受试者后提前终止,作者指出这些初步结果需在更大规模试验中证实。

对床旁实践的改变

  • 作者结论认为,在无ARDS的急性脑损伤患者中,与常规通气策略相比,肺保护性通气策略未降低死亡率、脱机患者比例或ARDS发生率,且在神经功能结局方面无获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Lung-protective strategies using low Vt and moderate positive end-expiratory pressure (PEEP) are considered best practice in critical care, but interventional trials have never been conducted in patients with acute brain injuries because of concerns about carbon dioxide control and the effect of PEEP on cerebral hemodynamics. Objectives: To test the hypothesis that ventilation with lower VT and higher PEEP compared to conventional ventilation would improve clinical outcomes in patients with acute brain injury. Methods: In this multicenter, open-label, controlled clinical trial, 190 adult patients with acute brain injury were assigned to receive either a lung-protective or a conventional ventilatory strategy. The primary outcome was a composite endpoint of death, ventilator dependency, and acute respiratory distress syndrome (ARDS) at Day 28. Neurological outcome was assessed at ICU discharge by the Oxford Handicap Scale and at 6 months by the Glasgow Outcome Scale. Measurements and Main Results: The two study arms had similar characteristics at baseline. In the lung-protective and conventional strategy groups, using an intention-to-treat approach, the composite outcome at 28 days was 61.5% and 45.3% (relative risk [RR], 1.35; 95% confidence interval [CI], 1.03-1.79; P = 0.025). Mortality was 28.9% and 15.1% (RR, 1.91; 95% CI, 1.06-3.42; P = 0.02), ventilator dependency was 42.3% and 27.9% (RR, 1.52; 95% CI, 1.01-2.28; P = 0.039), and incidence of ARDS was 30.8% and 22.1% (RR, 1.39; 95% CI, 0.85-2.27; P = 0.179), respectively. The trial was stopped after enrolling 190 subjects because of termination of funding. Conclusions: In patients with acute brain injury without ARDS, a lung-protective ventilatory strategy, as compared with a conventional strategy, did not reduce mortality, percentage of patients weaned from mechanical ventilation, or incidence of ARDS and was not beneficial in terms of neurological outcomes. Because of the early termination, these preliminary results require confirmation in larger trials. Clinical trial registered with www.clinicaltrials.gov (NCT01690819).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Mascia L, Fanelli V, Mistretta A, et al. Lung-Protective Mechanical Ventilation in Patients with Severe Acute Brain Injury: A Multicenter Randomized Clinical Trial (PROLABI). Am J Respir Crit Care Med. 2024. PMID: 39288368. doi:10.1164/rccm.202402-0375OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。